Table of Contents
Overview
New York, NY – May 07, 2025 – Global Myomectomy Market size is expected to be worth around USD 1688.3 Million by 2033 from USD 720.1 Million in 2023, growing at a CAGR of 8.9% during the forecast period from 2024 to 2033.
Myomectomy is a surgical procedure performed to remove uterine fibroids, which are non-cancerous growths that develop in or on the uterus. Unlike a hysterectomy, myomectomy preserves the uterus, making it an ideal option for women who wish to maintain fertility or avoid complete uterine removal.
This procedure is commonly recommended for women experiencing symptoms such as heavy menstrual bleeding, pelvic pain, pressure on the bladder, or infertility due to fibroids. Myomectomy can be performed using different techniques, including abdominal (open surgery), laparoscopic (minimally invasive), or hysteroscopic (through the cervix) methods. The choice of procedure depends on the size, number, and location of the fibroids.
Advancements in surgical technology, such as robotic-assisted laparoscopy and enhanced imaging, have significantly improved patient outcomes. These innovations have led to shorter recovery times, reduced blood loss, and minimal scarring. Myomectomy is considered a safe and effective treatment, with high success rates in symptom relief and reproductive outcomes.
Globally, the demand for myomectomy is rising due to increasing awareness of women’s reproductive health and a growing preference for fertility-preserving treatments. Healthcare providers are focusing on patient education and early diagnosis to manage fibroid-related complications more effectively. Myomectomy continues to be a critical option in gynecologic surgery, supporting both therapeutic and reproductive health goals.
Key Takeaways
- Market Size Outlook: The global myomectomy market is projected to reach approximately USD 1,688.3 million by 2033, up from USD 720.1 million in 2023, reflecting strong growth potential over the forecast period.
- Growth Rate: The market is anticipated to expand at a compound annual growth rate (CAGR) of 8.9% from 2024 to 2033, driven by rising demand for fertility-preserving fibroid treatments and advancements in surgical techniques.
- Type Segment Insights: As of 2023, abdominal myomectomy remains the leading procedural type, accounting for 38.41% of the total market share, owing to its effectiveness in treating larger or multiple fibroids.
- Product Segment Overview: In the product category, laparoscopic sealers dominate with a 25.16% share in 2023, supported by the growing preference for minimally invasive surgeries.
- End-Use Analysis: Hospitals and clinics represent the largest end-user segment, capturing 41.57% of the market share in 2023, attributed to their advanced surgical capabilities and higher patient intake volumes.
- Regional Landscape: North America leads the global myomectomy market, commanding 43.30% of the share in 2023, driven by a well-established healthcare infrastructure and widespread adoption of advanced surgical technologies.
- Technological Advancements: The market is being transformed by the adoption of minimally invasive and robotic-assisted surgeries, with systems like the da Vinci robotic platform significantly improving surgical precision and patient recovery times.
- Emerging Opportunities: Growth prospects are further supported by expanding access in emerging markets, technological innovations, and supportive government initiatives focused on women’s reproductive health.
Segmentation Analysis
- Type Analysis: The myomectomy market is segmented by surgical methods used to remove fibroids. In 2023, abdominal myomectomy dominated with 38.41% market share, due to its effectiveness in removing large or multiple fibroids. Hysteroscopic myomectomy, suited for smaller fibroids, offers quicker recovery and fewer complications. Laparoscopic myomectomy, a minimally invasive technique, is increasingly preferred for its reduced scarring and faster recovery. Each approach caters to different clinical needs, contributing distinctly to overall market dynamics.
- Product Analysis: Product segmentation in the myomectomy market is shaped by devices supporting surgical precision. In 2023, laparoscopic sealers led with a 25.16% share, enhancing vessel sealing and minimizing blood loss. Power morcellators remain important but face regulatory scrutiny due to safety concerns. The harmonic scalpel, using ultrasonic energy, allows precise cutting and coagulation, reducing tissue damage. These tools collectively improve surgical outcomes and are central to the market’s technological advancement.
- End-User Analysis: Hospitals and clinics dominated the myomectomy market in 2023, capturing 41.57% share, driven by advanced infrastructure and skilled surgical teams. These facilities are ideal for managing complex procedures and ensuring quality post-operative care. Ambulatory Surgical Centers (ASCs) also contribute significantly, offering cost-effective, same-day surgeries with efficient care delivery. Both segments cater to different patient needs and influence treatment access, shaping the broader landscape of fibroid surgery services.
Market Segments
By Type
- Abdominal Myomectomy
- Hysteroscopic Myomectomy
- Laparoscopic Myomectomy
By Product
- Laparoscopic Sealer
- Laparoscopic Power Morcellators
- Harmonic Scalpel
- Others
By End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
Regional Analysis
In 2023, North America accounted for 43.30% of the global myomectomy market, establishing itself as the leading regional segment. This strong market position is attributed to the region’s well-developed healthcare infrastructure, high availability of experienced surgical specialists, and the widespread incidence of uterine fibroids.
The region’s early adoption of minimally invasive and robotic-assisted surgical technologies further strengthens its market leadership. Additionally, increased public awareness, routine gynecological screenings, and supportive health policies related to fibroid management contribute to the high volume of myomectomy procedures. These combined factors continue to reinforce North America’s dominant role in the global myomectomy market.
Emerging Trends
- Shift Toward Minimally Invasive Techniques: There has been a significant increase in the adoption of minimally invasive myomectomy (MIM) procedures. Data indicates that the proportion of laparoscopic MIM rose from 6.0% in 2009 to 24.9% in 2019, while robotic-assisted MIM increased from 3.6% to 8.5% during the same period . These techniques are associated with benefits such as reduced blood loss, shorter hospital stays, and quicker recovery times.
- Advancements in Robotic-Assisted Surgery: Robotic-assisted laparoscopic myomectomy (RALM) has emerged as a viable alternative to open surgery. Advantages include shorter hospital stays, less postoperative pain, and faster return to normal activities . However, considerations such as higher costs and longer operative times remain.
- Demographic Considerations: The majority of women undergoing myomectomy are between the ages of 31 and 40 years, accounting for approximately 55.9% of cases . This demographic trend underscores the importance of fertility-preserving surgical options.
Use Cases
- Prevalence and Incidence: Uterine fibroids are a common gynecological condition. A study identified 16,046 new cases, with an incidence rate of 63.5 per 10,000 person-years . Myomectomy serves as a primary surgical intervention for symptomatic fibroids, particularly in women desiring uterine preservation.
- Safety Profile: An analysis of 23,549 women aged 15–55 years who underwent myomectomy reported a mortality rate of 1.3 per 10,000 patients. The incidence rates for venous thromboembolism, deep vein thrombosis, and pulmonary embolism were 5.7, 4.4, and 2.5 per 10,000 patients, respectively . These findings suggest that myomectomy is generally a safe procedure with low complication rates.
- Postoperative Outcomes: Comparative studies indicate that patients undergoing RALM experience shorter hospital stays (1.5 days vs. 2.7 days) and quicker return to work (85.7% within one month) compared to those undergoing abdominal myomectomy . However, RALM is associated with longer operative times and may result in a higher residual fibroid burden.
Conclusion
The global myomectomy market is experiencing steady growth, driven by rising awareness of uterine fibroids, a growing preference for fertility-preserving procedures, and significant advancements in minimally invasive and robotic-assisted surgical technologies. With a projected market value of USD 1,688.3 million by 2033 and a CAGR of 8.9%, the demand for effective, safe, and uterus-conserving treatments continues to rise.
North America leads the market due to its advanced healthcare infrastructure and early adoption of surgical innovations. As demographic trends and clinical needs evolve, myomectomy remains a vital solution in women’s reproductive healthcare, offering improved outcomes and broader access to treatment.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
